| Current, New and future therapeutic targets in inflammatory bowel disease: a systematic review N Alimohammadi, F Koosha, M Rafeian-Kopaei Current Pharmaceutical Design 26 (22), 2668-2675, 2020 | 13 | 2020 |
| The exosomes: staring biomarkers and novel therapeutic strategies F Koosha, N Alimohammadi, M Rafeian-Kopaei Current Pharmaceutical Design 27 (35), 3714-3721, 2021 | 8 | 2021 |
| Lung cancer risk and the inhibitors of angiotensin converting enzyme; an updated review on recent evidence M Khosravian, M Momenzadeh, F Koosha, N Alimohammadi, N Kianpour Immunopathologia Persa 8 (1), e19-e19, 2021 | 6 | 2021 |
| COVID-19-associated glomerulopathy and high-risk apol1 genotype; basis for a two-hit mechanism of injury? A narrative review on recent findings A Pezeshgi, M Mubarak, A Djamali, L Mostafavi, S Moghadam-Kia, ... Journal of Nephropathology 10 (2), 1-7, 2021 | 5 | 2021 |
| Association of serum fibroblast growth factor 23 with calcium metabolism in patients with end-stage renal disease undergoing hemodialysis. N Alimohammadi, P Javadian, A Malekpour, S Tahmasebian Journal of Nephropathology 6 (4), 2017 | 2 | 2017 |
| Ameliorative effects of pirfenidone in chronic kidney disease S Ghodrati, YR Haghi, J Baharani, A Joseph, N Alimohammadi, F Koosha, ... Journal of Nephropharmacology 11 (2), e10458-e10458, 2022 | 1 | 2022 |
| Therapeutic effects of curcumin on kidney disease; an updated review of the current knowledge L Saberian, N Alimohammadi, F Koosha, HV Rahvard, K Ahmadi, ... J Ren Endocrinol 8, e23063, 2022 | | 2022 |
| Journal of Nephropathology N Alimohammadi, P Javadian, A Malekpour, S Tahmasebian | | |
